HLK Pharmacin

HLK Pharmacin is a global biotechnology company specializing in the development of value-added therapeutics through innovative formulation technologies. Headquartered in Shenzhen, China, with a key subsidiary in New Haven, Connecticut, the company focuses on the 505(b)(2) regulatory pathway to reformulate existing drugs for improved bioavailability, safety, and patient compliance. Its pipeline includes clinical-stage programs for anaphylaxis, psoriasis, and breast cancer, as well as preclinical candidates in oncology and psychiatry. HLK Pharmacin leverages proprietary platforms such as spray drying and peptide oral delivery to address unmet medical needs across multiple therapeutic areas.